-
公开(公告)号：US20220242901A1
公开(公告)日：2022-08-04
申请号：US17672072
申请日：2022-02-15
摘要： The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
-
公开(公告)号：US20200171051A1
公开(公告)日：2020-06-04
申请号：US16697808
申请日：2019-11-27
IPC分类号： A61K31/573 , A61K47/54 , A61K47/64
摘要： The present invention relates to methods for treating acute kidney injury that utilize a glucocorticoid prodrug. The glucocorticoid prodrug selectively delivers a glucocorticoid to the kidney, where it is capable of eliciting a p21 protective response. The present invention also contemplates several novel glucocorticoid prodrugs capable of use in the above manner.
-
公开(公告)号：US20240002427A1
公开(公告)日：2024-01-04
申请号：US18243584
申请日：2023-09-07
CPC分类号： C07H23/00 , A61K9/0019 , A61K9/08 , A61K31/409
摘要： The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
-
4.发明申请公开(公告)号：US20200281871A1
公开(公告)日：2020-09-10
申请号：US16811759
申请日：2020-03-06
IPC分类号： A61K31/12 , A61K9/127 , A61K47/24 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/145 , A61K31/16 , A61K31/7048 , A61K47/10 , A61K47/34
摘要： The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.
-
公开(公告)号：US20210322340A1
公开(公告)日：2021-10-21
申请号：US17210205
申请日：2021-03-23
摘要： The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.
-
公开(公告)号：US20200057076A1
公开(公告)日：2020-02-20
申请号：US16422156
申请日：2019-05-24
IPC分类号： G01N33/68 , A61K31/277 , A61K33/26 , A61K31/409
摘要： The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
-
公开(公告)号：US20230314448A1
公开(公告)日：2023-10-05
申请号：US17873968
申请日：2022-07-26
IPC分类号： A61K31/277 , A61K31/409 , G01N33/68 , A61K33/26
CPC分类号： G01N33/6893 , A61K31/277 , A61K31/409 , A61K33/26 , G01N2800/347
摘要： The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
-
公开(公告)号：US20230070012A1
公开(公告)日：2023-03-09
申请号：US17979490
申请日：2022-11-02
摘要： The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
-
公开(公告)号：US20210338708A1
公开(公告)日：2021-11-04
申请号：US17205521
申请日：2021-03-18
IPC分类号： A61K31/714 , A61K33/30 , A61K33/24 , A61K47/54 , A61K9/00 , A61P31/14 , A01N25/34 , A01N55/04 , A01N55/02 , A61L9/012
摘要： The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.
-
公开(公告)号：US20210308074A9
公开(公告)日：2021-10-07
申请号：US16811759
申请日：2020-03-06
IPC分类号： A61K31/12 , A61K9/127 , A61K47/24 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/145 , A61K31/16 , A61K31/7048 , A61K47/10 , A61K47/34
摘要： The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.021 秒)
